

## Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice

Carmen Fava,<sup>1</sup> Giovanna Rege-Cambrin,<sup>1</sup> Irene Dogliotti,<sup>1</sup> Marco Cerrano,<sup>2</sup> Paola Berchiolla,<sup>1</sup> Matteo Dragani,<sup>1</sup> Gianantonio Rosti,<sup>3</sup> Fausto Castagnetti,<sup>3</sup> Gabriele Gugliotta,<sup>3</sup> Bruno Martino,<sup>4</sup> Carlo Gambacorti-Passerini,<sup>5</sup> Elisabetta Abruzzese,<sup>6</sup> Chiara Elena,<sup>7</sup> Patrizia Pregno,<sup>8</sup> Antonella Gozzini,<sup>9</sup> Isabella Capodanno,<sup>10</sup> Micaela Bergamaschi,<sup>11</sup> Monica Crugnola,<sup>12</sup> Monica Bocchia,<sup>13</sup> Sara Galimberti,<sup>14</sup> Davide Rapezzi,<sup>15</sup> Alessandra Iurlo,<sup>16</sup> Daniele Cattaneo,<sup>16</sup> Roberto Latagliata,<sup>17</sup> Massimo Breccia,<sup>17</sup> Michele Cedrone,<sup>18</sup> Marco Santoro,<sup>19</sup> Mario Annunziata,<sup>20</sup> Luciano Levato,<sup>21</sup> Fabio Stagno,<sup>22</sup> Francesco Cavazzini,<sup>23</sup> Nicola Sgherza,<sup>24</sup> Valentina Giai,<sup>25</sup> Luigia Luciano,<sup>26</sup> Sabina Russo,<sup>27</sup> Pellegrino Musto,<sup>28</sup> Giovanni Caocci,<sup>29</sup> Federica Sorà,<sup>30</sup> Francesco Iuliano,<sup>31</sup> Francesca Lunghi,<sup>32</sup> Giorgina Specchia,<sup>33</sup> Fabrizio Pane,<sup>26</sup> Dario Ferrero,<sup>2</sup> Michele Baccarani<sup>3</sup> and Giuseppe Saglio<sup>1</sup>

<sup>1</sup>Department of Clinical and Biological Sciences, University of Turin, Orbassano; <sup>2</sup>Hematology Division, Department of Molecular Biotechnologies and Health Sciences, University of Turin, Turin; <sup>3</sup>Institute of Hematology "L. & A. Seràgnoli", St. Orsola University Hospital, Bologna; <sup>4</sup>Azienda Ospedaliera "Bianchi Melacrino Morelli", Reggio Calabria; <sup>5</sup>University Milano Bicocca, San Gerardo Hospital, Monza; <sup>6</sup>Haematology Unit, S. Eugenio Hospital, Rome; <sup>7</sup>Hematology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia; <sup>8</sup>A.O. Città della Salute e della Scienza di Torino, Turin; <sup>9</sup>SC Terapie Cellulari e Medicina Trasmfusionale, AOU Careggi, Florence; <sup>10</sup>Hematology, Azienda Unità Sanitaria Locale - IRCCS, Reggio Emilia; <sup>11</sup>Division of Hematology 1, IRCCS AOU San Martino-IST, Genoa; <sup>12</sup>Division of Hematology, University Hospital of Parma, Parma; <sup>13</sup>Azienda Ospedaliera Universitaria, University of Siena, Siena; <sup>14</sup>Hematology Department, University of Pisa, Pisa; <sup>15</sup>S.C. Ematologia, ASO S. Croce e Carle, Cuneo; <sup>16</sup>Haematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan; <sup>17</sup>Department of Cellular Biotechnologies and Hematology, University La Sapienza, Rome; <sup>18</sup>UOC of Hematology, San Giovanni - Addolorata Hospital, Rome; <sup>19</sup>Hematology Unit, University of Palermo, Palermo; <sup>20</sup>Division of Hematology, Ospedale Cardarelli, Naples; <sup>21</sup>Department Hematology-Oncology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro; <sup>22</sup>Chair and Hematology Section, Ferrarotto Hospital, Catania; <sup>23</sup>Department of Medical Sciences - Haematology and Physiopathology of Haemostasis Section, Ferrara; <sup>24</sup>Division of Hematology, IRCCS Ospedale Casa Sollievo Sofferenza, San Giovanni Rotondo; <sup>25</sup>Division of Haematology, SS Antonio e Biagio e Cesare Arrigo Hospital, Alessandria; <sup>26</sup>Division of Hematology - Departments of Clinical Medicine and Surgery, University of Naples Federico II, Naples; <sup>27</sup>Department of Internal Medicine, AOU Policlinico di Messina, Messina; <sup>28</sup>IRCCS, Centro Di Riferimento Oncologico Della Basilicata, Rionero in Vulture; <sup>29</sup>Department of Medical Sciences, University of Cagliari, Cagliari; <sup>30</sup>Hematology Department, University Cattolica del Sacro Cuore - Policlinico A. Gemelli, Rome; <sup>31</sup>Presidio Ospedaliero N. Giannetasio - Azienda ASL 3, Rossano; <sup>32</sup>Division of Haematology and Bone Marrow Transplant, Ospedale San Raffaele IRCCS, Milan and <sup>33</sup>Division of Haematology with Transplant - Outpatients, Azienda Ospedaliero-Universitaria Policlinico Consortoriale di Bari, Bari, Italy




©2019 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2018.205054

Received: October 8, 2018.

Accepted: February 27, 2019.

Pre-published: February 28, 2019.

Correspondence: CARMEN FAVA - carmen.fava@unito.it



**Suppl. 1.** Pattern of the frequency of relapses over the first 50 months after treatment discontinuation. A) Kaplan-Meier curves for the overall population; B) Kaplan-Meier curves for patients who discontinued imatinib; C) Kaplan-Meier curves for patients who discontinued 2<sup>nd</sup> generation Tyrosine Kinase Inhibitors.